Anna Chalecka-Przybylowicz

Poznan, WP, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Treatment of leukemic ocular infiltrations with intraarterial chemotherapy in very early mixed relapse of B-cell acute lymphoblastic leukemia.

Treatment of leukemic ocular infiltrations with intraarterial chemotherapy in very early mixed relapse of B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: January 10, 2026

Cytogenetic landscape aberrations in paediatric acute lymphoblastic leukaemia - a polish paediatric population treated according to ALL-IC BFM 2009 protocol.

Cytogenetic landscape aberrations in paediatric acute lymphoblastic leukaemia - a polish paediatric population treated according to ALL-IC BFM 2009 protocol.

Journal: Scientific reports

Published: February 03, 2025

Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

Journal: Blood

Published: February 13, 2024

Acute Myeloid Leukemia Post Cytotoxic Therapy in Breast Cancer Survivors-Over 23 Years of Single Center Analysis.

Acute Myeloid Leukemia Post Cytotoxic Therapy in Breast Cancer Survivors-Over 23 Years of Single Center Analysis.

Journal: Journal of clinical medicine

Published: December 14, 2023

The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.

The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.

Journal: Leukemia research

Published: January 23, 2023

BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.

BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases.

Journal: Molecular cytogenetics

Published: November 25, 2022

Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis.

Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis.

Journal: Polish archives of internal medicine

Published: September 27, 2022

Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study.

Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study.

Journal: Leukemia & lymphoma

Published: August 08, 2019

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.

Journal: Polish archives of internal medicine

Published: May 27, 2017

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Journal: Oncotarget

Published: December 08, 2016

Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).

Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).

Journal: Leukemia & lymphoma

Published: August 27, 2016

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.

Journal: Oncotarget

Published: June 08, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026